HANOVER, NH - Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal ...

The trials for this new TB vaccine have been taking place in sub-Saharan Africa for several years and the long-term Phase 2b results have finally been published.

Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal Vaccine.

The IMAGINE trial is a large-scale safety and efficacy clinical trial of the TB vaccine candidate MTBVAC. The study, sponsored by IAVI, is funded by Open Philanthropy, the Gates Foundation ...